Roquefort Therapeutics plc is a London-listed biotech that concentrates on discovering, developing, and in-licensing novel oncology drugs. Its current strategic objective is to obtain exclusive licence rights to AO-252, a first-in-class therapy that targets the TACC3 protein for cancer treatment. To advance this deal the company has engaged advisers and is drafting definitive agreements with A2A Pharmaceuticals and Coiled Therapeutics. The firm recently raised £300,000 specifically to cover the initial costs of this acquisition, underlining its dependence on external capital to execute its growth plans. Chairman Stephen West reinforced insider confidence by contributing £45,000 to the latest raise. The capital structure offered investors a 20 % discount to the price of the next placing and attached warrants, illustrating management’s willingness to use structured incentives to fund operations.

Total raised

$0M

Funding rounds

2

Latest round

Equity

Latest activity

Oct 2025